Last reviewed · How we verify

Saphnelo — Competitive Intelligence Brief

Saphnelo (ANIFROLUMAB) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Type I Interferon Receptor Antagonist [EPC]. Area: Immunology.

marketed Type I Interferon Receptor Antagonist [EPC] Interferon alpha/beta receptor 1 Immunology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Saphnelo (ANIFROLUMAB) — AstraZeneca. Saphnelo blocks the action of interferon alpha/beta, a protein that triggers an immune response.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Saphnelo TARGET ANIFROLUMAB AstraZeneca marketed Type I Interferon Receptor Antagonist [EPC] Interferon alpha/beta receptor 1 2021-01-01
SAPHNELO ANIFROLUMAB-FNIA ASTRAZENECA AB marketed Type I Interferon Receptor Antagonist [EPC] Interferon alpha/beta receptor 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Type I Interferon Receptor Antagonist [EPC] class)

  1. ASTRAZENECA AB · 1 drug in this class
  2. AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Saphnelo — Competitive Intelligence Brief. https://druglandscape.com/ci/anifrolumab. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: